Summary

Objective: evaluate the estrogenic effects of soy isoflavone in female patient in menopause phase.
Patients and Methods: 80 patients were evaluated inthe menopause phase in the Climacteric Syndrome Department of Gynecology Department of Universidade Federal de São Paulo – Escola Paulista de Medicina in the period between August and November 1999. The patients were subdivided into two groups of 40 women. Group 1 (G1) received oral administration of a 100 mg capsule (shared in 3 steps) and Group 2 received placebo. In the study inclusion, the patients have shown menopausal clinical symptom evaluated by Kupperman index and gonadotrofines laboratory changes.
Results: regarding menopausal symptom evaluated by Kupperman, 80% of the G1 patients improved and in the G2 Group the improvement was 12,5%. Referring to plasmatic cholesterol level, 35 patients from G1 with levels above 200 mg/dl, we notice a significant plasmatic cholesterol decrease, on the other hand, in the G2 Group the cholesterol levels decrease was verified only in 13 of them. Regarding body weight we could notice a IMC reduction in G1 Group patients while in G2 Group patients theses values were stable. We also have notice that some parameters such as endometrial density, estradiol level changes and blood FSH did not shown any significant changes.
Conclusion: according to this study we could conclude 100 mg/day Isoflavone intake might contribute to the treatment of menopausal changes in order to attenuate its symptoms, decrease plasmatic cholesterol levels and body weight.